WebApr 15, 2024 · Clinical Trial NCT03918109; OTO-313 in Subjects With Subjective Tinnitus December 2, 2024 updated by: Otonomy, Inc. A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus. WebFeb 22, 2024 · A Phase 1/2 trial of OTO-313 in patients with unilateral tinnitus of at least moderate severity demonstrated a positive clinical response for OTO-313 using the …
OTO-313 in Subjects With Unilateral Subjective Tinnitus
WebApr 2, 2024 · Subject has early-onset subjective unilateral tinnitus that is persistent (consistently aware of their tinnitus throughout much of the waking day). Subject is able … WebJun 16, 2024 · The OTO-313 trial is evaluating the effectiveness of an investigational drug (a drug that has not been approved for use outside of clinical research studies) to help … lawn mower and appliance dealer near me
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 …
WebAug 1, 2024 · The randomized, double-blind, placebo-controlled Phase 2 trial enrolled 153 patients with persistent, unilateral tinnitus of at least moderate severity. Patients were randomized 1:1 to a single... WebJul 9, 2024 · The study, “A Randomized, Double-blind, Placebo-controlled Phase 2 Study of OTO-313 Given as a Single Intratympanic Injection,” began in March 2024 and … WebOTO-313 2024 Completed Phase 2 ~50 Trial Logistics Trial Timeline Screening: ~3 weeks Treatment: Varies Reporting: week 4, week 8, week 12, week 16 Who is running the clinical trial? Otonomy, Inc. Lead Sponsor 21 Previous Clinical Trials 2,926 Total Patients Enrolled 1 Trials studying Tinnitus 43 Patients Enrolled for Tinnitus Eligibility Criteria kally\u0027s mashup streaming